Paik JJ, Casciola‐Rosen L, Shin JY, et al. - An open‐label 12‐week study was performed to assess the effectiveness and safety of tofacitinib, a JAK inhibitor, in treatment‐refractory active dermatomyositis (DM). Ten individuals with DM received tofacitinib in extended‐release doses of 11 mg. This is the first prospective, open‐label clinical trial of tofacitinib in DM that indicates strong clinical effectiveness of a pan‐JAK inhibitor, as assessed by validated myositis response criteria. Using JAK inhibitors, further randomized controlled trials should be considered for treating DM.